(Vidarabine Ophthalmic Ointment, USP) 3%
VIRA-A is the trade name for vidarabine (also known as adenine arabinoside and Ara-A), an antiviral drug for the topical treatment of epithelial keratitis caused by Herpes simplex virus.
VIRA-A Ophthalmic Ointment, 3%, is indicated for the treatment of acute keratoconjunctivitis and recurrent epithelial keratitis due to Herpes simplex virus types l and 2. The clinical diagnosis of keratitis caused by Herpes simplex virus is usually established by the presence of typical dendritic or geographic lesions on slit-lamp examination. It is also effective in superficial keratitis caused by Herpes simplex virus which has not responded to topical idoxuridine or when toxic or hypersensitivity reactions due to idoxuridine have occurred. The effectiveness of VIRA-A Ophthalmic Ointment, 3%, against stromal keratitis and uveitis due to Herpes simplex virus has not been established.
Published Studies Related to Vira-A (Vidarabine Topical)
Antiviral agents for treatment of herpes simplex virus infection in neonates. [2009.07.08]
CONCLUSIONS: There is insufficient trial evidence to evaluate the effects of antiviral agents with controls or with each other. The rarity of the condition makes effectively powered clinical trials difficult to perform. The efficacy of newer antiviral agents with better bioavailability (e.g. valaciclovir, valganciclovir) for the treatment of neonatal disease needs to be evaluated in randomised trials. The efficacy of oral formulations need to be evaluated as they may be useful for infants with skin, eye or mouth HSV disease or in the treatment of infants with recurrences after the neonatal period.
Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. [1992.03]
Seventy-three immunocompromised patients with disseminated herpes zoster were evaluated in a double-blind controlled trial of acyclovir (n = 37) versus vidarabine (n = 36) therapy. Acyclovir was administered at 30 mg/kg/day at 8-h intervals and vidarabine was given as a continuous 12-h infusion at 10 mg/kg/day for 7 days (longer if resolution of cutaneous or visceral disease was incomplete)...
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. [1991.08.22]
BACKGROUND AND METHODS... Once the treatment is stopped, however; there is a high frequency of relapse.
A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. [1991.02.14]
BACKGROUND.The study lacked statistical power to determine whether there were sizable differences within the subgroups of those with localized HSV, encephalitis, or disseminated disease.
Current therapy of varicella zoster virus infection in immunocompromised patients. A comparison of acyclovir and vidarabine. [1988.08.29]
Both acyclovir and vidarabine are effective treatment for varicella zoster virus (VZV) infection in immunosuppressed patients. To determine which is preferable, therapy with these two agents was compared in a prospective, randomized trial...
Page last updated: 2009-10-20